View Older Stories View More Recent Stories

Feb 28, 2023 04:03PM Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update
Feb 21, 2023 07:00AM Syndax to Announce Fourth Quarter and Year-end 2022 Financial Results and Host Conference Call and Webcast on February 28, 2023
Feb 14, 2023 07:00AM Syndax Announces Participation at Upcoming Investor Conferences
Jan 4, 2023 07:00AM Syndax Announces Presentation at 41st Annual J.P. Morgan Healthcare Conference
Dec 10, 2022 05:00PM Syndax Announces Positive Updated Data from Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias During Oral Presentations at 64th ASH Annual Meeting
Dec 8, 2022 05:06PM Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Dec 5, 2022 07:16AM Syndax Pharmaceuticals (SNDX) Announces U.S. FDA Breakthrough Therapy Designation Granted for Revumenib for the Treatment of Adult and Pediatric Patients with Relapsed or Refractory KMT2A- Rearranged
Dec 5, 2022 07:15AM Syndax Announces U.S. FDA Breakthrough Therapy Designation Granted for Revumenib for the Treatment of Adult and Pediatric Patients with Relapsed or Refractory KMT2A- Rearranged (MLLr) Acute Leukemia
Dec 5, 2022 07:06AM Syndax Pharmaceuticals (SNDX) and Incyte (INCY) Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology
Dec 5, 2022 07:00AM Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology
Dec 2, 2022 07:00AM Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer
Nov 21, 2022 07:00AM Syndax Announces Participation at Evercore ISI Annual HealthCONx Conference
Nov 3, 2022 04:05PM Syndax Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Business Update
Nov 3, 2022 09:03AM Syndax Pharmaceuticals (SNDX) Reports Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of AUGMENT-101 Trial
Nov 3, 2022 09:00AM Syndax Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias
Oct 27, 2022 07:00AM Syndax to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022
Aug 8, 2022 04:05PM Syndax Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update
Aug 2, 2022 07:00AM Syndax to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 8, 2022
Jun 16, 2022 04:30PM Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Jun 13, 2022 07:32AM Syndax Pharmaceuticals (SNDX) Announces Appointment of Keith A. Goldan as Chief Financial Officer
Jun 13, 2022 07:30AM Syndax Pharmaceuticals Announces Appointment of Keith A. Goldan as Chief Financial Officer
May 26, 2022 07:00AM Syndax Announces Participation at Two Upcoming Investor Conferences
May 11, 2022 07:00AM Syndax Announces Participation at Citi's Biopharma Virtual Co-Panel Day
May 9, 2022 04:05PM Syndax Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Business Update
May 2, 2022 07:00AM Syndax to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 9, 2022
Mar 4, 2022 04:05PM Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Mar 1, 2022 04:05PM Syndax Pharmaceuticals Reports Fourth Quarter 2021 Financial Results and Provides Clinical and Business Update
Mar 1, 2022 04:01PM Syndax Pharmaceuticals (SNDX) Appoints Kate Madigan as Chief Medical Officer
Mar 1, 2022 04:01PM Syndax Pharmaceuticals Announces Appointment of Kate Madigan, M.D., as Chief Medical Officer
Feb 28, 2022 07:00AM Syndax Announces Participation at Two Upcoming Investor Conferences
Feb 22, 2022 07:00AM Syndax to Announce Fourth Quarter and Year-end 2021 Financial Results and Host Conference Call and Webcast on March 1, 2022
Feb 8, 2022 07:30AM Soligenix to Present at the 2022 BIO CEO & Investor Conference
Feb 3, 2022 04:04PM Syndax Pharmaceuticals (SNDX) Announces CEO Transition
Feb 3, 2022 04:01PM Syndax Pharmaceuticals Announces Transition of Michael A. Metzger to Chief Executive Officer; Briggs W. Morrison, M.D., to Assume Role of President, Head of Research & Development
Jan 20, 2022 07:00AM Syndax Announces Presentation at B. Riley Securities' 2022 Oncology Conference
Jan 7, 2022 07:00AM Syndax Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference
Dec 22, 2021 07:01AM Syndax Pharmaceuticals' (SNDX) SNDX-5613 Granted Orphan Drug Designation in Europe for Treatment of Acute Myeloid Leukemia
Dec 22, 2021 07:00AM Syndax Announces Orphan Drug Designation Granted to SNDX-5613 by European Commission for the Treatment of Acute Myeloid Leukemia
Dec 13, 2021 02:46PM Syndax Pharmaceuticals (SNDX) Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613
Dec 13, 2021 02:45PM Syndax Pharmaceuticals Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613
Dec 13, 2021 05:13AM Syndax Pharmaceuticals (SNDX) Reports Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease
Dec 11, 2021 02:00PM Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease
Dec 9, 2021 04:05PM Syndax Pharmaceuticals Announces Closing of Global Collaboration and License Agreement for Axatilimab
Nov 15, 2021 04:05PM Syndax Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Business Update
Nov 8, 2021 07:00AM Syndax to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 15, 2021
Nov 4, 2021 09:24AM Syndax Pharmaceuticals to Present Updated Data from SNDX-5613 and Axatilimab Clinical Programs During Oral Sessions at 63rd ASH Annual Meeting
Sep 27, 2021 06:13AM Syndax Pharmaceuticals (SNDX) and Incyte (INCY) Announce Pact for Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases
Sep 27, 2021 06:00AM Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases
Sep 15, 2021 04:02PM Syndax Pharmaceuticals (SNDX) Appoints Martin H. Huber to its Board
Sep 15, 2021 04:01PM Syndax Appoints Martin H. Huber, M.D., to its Board of Directors
View More Recent Stories View Older Stories